Johnson & Johnson announced that their drug combination RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations. This result, presented at ASCO 2026, marks a significant improvement over current treatments, which typically offer less than two years of survival. The combination targets multiple disease drivers and showed consistent responses across mutation subgroups, including those with historically poor outcomes. These findings reinforce the potential of RYBREVANT-based regimens as a durable first-line treatment option for this difficult-to-treat cancer subtype.
Johnson & Johnson announced positive Phase 3 results from the MajesTEC-9 study, showing TECVAYLI (teclistamab-cqyv) significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients treated as early as s...
Johnson & Johnson announced FDA approval for an updated label on TREMFYA (guselkumab), highlighting its ability to inhibit structural joint damage progression in adults with active psoriatic arthritis (PsA). This update is based on positive 24-week P...
